Rare Community Profiles: Understanding MAC Lung Disease, Bronchiectasis, and PAH: A Discussion with Dr. Martina Flammer
source: pixabay.com

Rare Community Profiles: Understanding MAC Lung Disease, Bronchiectasis, and PAH: A Discussion with Dr. Martina Flammer

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: Understanding MAC Lung Disease, Bronchiectasis, and PAH: A Discussion with Dr. Martina Flammer

Researchers Seek Reason for a Higher Survival Rate in Obese Patients with Pulmonary Arterial Hypertension (PAH)

Pulmonary arterial hypertension (PAH) occurs when the pressure in blood vessels that transport blood from the heart to the lungs is unusually high. The results of seventeen clinical trials involving…

Continue Reading Researchers Seek Reason for a Higher Survival Rate in Obese Patients with Pulmonary Arterial Hypertension (PAH)

Study Identifies People with Idiopathic Pulmonary Arterial Hypertension at Greatest Risk of Death

Korea began its use of effective therapies for idiopathic pulmonary arterial hypertension (IPAH) early in 2000. Idiopathic hypertension has no apparent cause. Yet there have been very few studies assessing…

Continue Reading Study Identifies People with Idiopathic Pulmonary Arterial Hypertension at Greatest Risk of Death
An Opportunity for Junior Investigators to Make an Impact on PAH Research
https://pixabay.com/photos/student-notebook-female-study-type-865073/

An Opportunity for Junior Investigators to Make an Impact on PAH Research

The Pulmonary Hypertension Association recently announced it is offering junior investigators who are interested in pulmonary arterial hypertension (PAH) a two-year grant. Pulmonary Arterial Hypertension (PAH) Pulmonary arterial hypertension (PAH)…

Continue Reading An Opportunity for Junior Investigators to Make an Impact on PAH Research
FDA Clears IND Application for Phase II Pulmonary Arterial Hypertension Trial
source: pixabay.com

FDA Clears IND Application for Phase II Pulmonary Arterial Hypertension Trial

According to a story from news.cision.com, the US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for CS1, an investigational drug being developed by the…

Continue Reading FDA Clears IND Application for Phase II Pulmonary Arterial Hypertension Trial
Study: The Effect of Patient Support Groups on Pulmonary Hypertension Patients and their Caregivers
rawpixel / Pixabay

Study: The Effect of Patient Support Groups on Pulmonary Hypertension Patients and their Caregivers

There are seven major categories of support groups including mental and emotional support, addiction, bereavement, or medical support. The latter groups are designed for patients according to a specific disease.…

Continue Reading Study: The Effect of Patient Support Groups on Pulmonary Hypertension Patients and their Caregivers
Generic Treprostinil for PAH Now Offers Subcutaneous Administration
whitesession / Pixabay

Generic Treprostinil for PAH Now Offers Subcutaneous Administration

  In 2019, generic pharmaceuticals and biosimilars leader Sandoz launched intravenous treprostinil for patients with pulmonary arterial hypertension (PAH). But according to a new media release, generic treprostinil is now…

Continue Reading Generic Treprostinil for PAH Now Offers Subcutaneous Administration